Scholarlink

<p>Neoadjuvant cisplatin-based chemotherapy (NAC) confers a survival benefit in muscle-invasive bladder cancer (MIBC), however a relevant proportion of patients experience early disease recurrence following radical cystectomy. We conducted a multicenter observational study to evaluate clinical, pathological, and laboratory factors associated with early recurrence defined as disease-free survival [DFS] ≤ 12 months in patients with MIBC treated with neoadjuvant cisplatin plus gemcitabine followed by radical cystectomy. Early recurrence was significantly associated with aggressive pathological features, including higher ypT stage, nodal involvement, lymphovascular invasion, and lower rates of pathological complete response. Patients experiencing early recurrence predominantly presented with systemic dissemination and had significantly shorter DFS and overall survival (OS). Variant histology and the presence of post-treatment lymphovascular invasion were independently associated with early recurrence. Early recurrence after NAC identifies a subgroup of patients with aggressive clinicopathological features and poorer oncological outcomes, highlighting the need for improved postoperative risk stratification and novel perioperative treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Giandomenico Roviello,
  • Elisabetta Gambale,
  • Roberta Giorgione,
  • Umberto Basso,
  • Maria Oliveri,
  • Malvina Cremante,
  • Francesco Atzori,
  • Sarah Scagliarini,
  • Cristina Masini,
  • Valentina Baldazzi,
  • Federico Scolari,
  • Marinella Micol Mela,
  • Eleonora Lai,
  • Ismaela Anna Vascotto,
  • Virginia Rossi,
  • Chiara Calandrelli,
  • Daniele Rossini,
  • Daniele Lavacchi,
  • Sergio Serni,
  • Andrea Minervini,
  • Serena Pillozzi,
  • Lorenzo Antonuzzo

摘要

Neoadjuvant cisplatin-based chemotherapy (NAC) confers a survival benefit in muscle-invasive bladder cancer (MIBC), however a relevant proportion of patients experience early disease recurrence following radical cystectomy. We conducted a multicenter observational study to evaluate clinical, pathological, and laboratory factors associated with early recurrence defined as disease-free survival [DFS] ≤ 12 months in patients with MIBC treated with neoadjuvant cisplatin plus gemcitabine followed by radical cystectomy. Early recurrence was significantly associated with aggressive pathological features, including higher ypT stage, nodal involvement, lymphovascular invasion, and lower rates of pathological complete response. Patients experiencing early recurrence predominantly presented with systemic dissemination and had significantly shorter DFS and overall survival (OS). Variant histology and the presence of post-treatment lymphovascular invasion were independently associated with early recurrence. Early recurrence after NAC identifies a subgroup of patients with aggressive clinicopathological features and poorer oncological outcomes, highlighting the need for improved postoperative risk stratification and novel perioperative treatment strategies.